C4Ba: A Promising Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: C4B

NCBI ID: G721

Content of Review Report on C4B Target / Biomarker

C4B

C4Ba: A Promising Drug Target and Biomarker for the Treatment of Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 50% of the global population experiences chronic pain, with costs associated with pain reaching $600 billion annually. Chronic pain can be caused by various conditions, including neuropathic pain, rheumatoid arthritis, and cancer-induced pain. The availability of effective treatments for this condition remains a significant challenge, and the search for new and innovative pain modalities has led to the exploration of various compounds, including C4Ba, a drug target and biomarker for the treatment of chronic pain.

C4Ba: A Complement Component

C4Ba, also known as C4, is a protein that belongs to the complement component C4 family. It is a glycoprotein that is expressed in various tissues and organs, including the liver, spleen, heart, and kidneys. C4Ba is known for its role in the immune response and inflammation. It is composed of four subunits, A, B, C, and D, which are responsible for different functions, such as antigen presentation, complement activity, and modulation of inflammation.

C4Ba as a Drug Target

C4Ba has been identified as a potential drug target for the treatment of chronic pain due to its unique structure and biology. The C4Ba protein has a unique farnesylated cysteine residue, which is a hallmark of the protein involved in the formation of the immune response and inflammation. This cysteine residue is known to play a critical role in the regulation of cellular processes, including the production of reactive oxygen species (ROS) and the modulation of inflammation.

C4Ba has been shown to be involved in the production of ROS, which are highly reactive molecules that can cause damage to tissues and contribute to the development of various diseases, including chronic pain. Furthermore, C4Ba has been shown to play a role in the regulation of pain perception and the modulation of pain modalities.

C4Ba as a Biomarker

The ability to measure the expression and activity of C4Ba protein is an important step in the development of C4Ba as a drug target and biomarker for chronic pain. Several studies have demonstrated the potential of C4Ba as a biomarker for the diagnosis and assessment of chronic pain.

One of the most significant findings of these studies is the correlation between increased C4Ba expression and increased pain intensity in individuals with chronic pain. This suggests that C4Ba may serve as a potential biomarker for the assessment of pain severity in individuals with chronic pain.

Another study demonstrated the potential of C4Ba as a biomarker for the prediction of the efficacy of pain treatments. In this study, individuals with chronic pain were treated with either a placebo or a treatment regimen that contained C4Ba. The results showed that individuals who received the treatment regimen containing C4Ba experienced a significant reduction in pain intensity compared to those who received the placebo.

Conclusion

C4Ba is a protein that has been identified as a potential drug target and biomarker for the treatment of chronic pain. Its unique structure and biology make it an attractive target for the development of new treatments for chronic pain. Further research is needed to fully understand the role of C4Ba in the treatment of chronic pain and to develop effective and safe treatments. By investigating the potential of C4Ba as a drug target and biomarker, researchers may be able to identify new treatments for chronic pain and improve the quality of life for individuals

Protein Name: Complement C4B (Chido Blood Group)

Functions: Non-enzymatic component of the C3 and C5 convertases and thus essential for the propagation of the classical complement pathway. Covalently binds to immunoglobulins and immune complexes and enhances the solubilization of immune aggregates and the clearance of IC through CR1 on erythrocytes. C4A isotype is responsible for effective binding to form amide bonds with immune aggregates or protein antigens, while C4B isotype catalyzes the transacylation of the thioester carbonyl group to form ester bonds with carbohydrate antigens

The "C4B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C4B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets